RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca

About this trial

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB/IIIC not eligible for curative-intent therapies or stage IV/M1 (a/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)

Aged at least 18 years at first diagnosis of a/m NSCLC

For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.

For the non_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)

Disqualifiers

Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts.

Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.

Trial population

The study population will consist of sequential adult patients in study sites with a diagnosis of IIIB/IIIC/IV non-squamous NSCLC with or without AGA and received at least 1 line of treatment after failing PTC for a/m NSCLC with a start date between January 2017 and December 2024.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Describe the patient population and treatment patterns

Description of patient population and treatment patterns: tumor histology, mutation and PD-L1 status, disease stage at diagnosis

Time frame
between January 1st 2017 and December 31th 2024
2

Describe the patient population and treatment patterns

Description of patient population and treatment patterns: disease stage at diagnosis

Time frame
between January 1st 2017 and December 21th 2024
3

Describe the patient population and treatment patterns

Description of patient population and treatment patterns: smoking status

Time frame
between January 1st 2017 and December 21th 2024
4

Describe the patient population and treatment patterns

Description of patient population and treatment patterns: age

Time frame
between January 1st 2017 and December 31th 2024

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.